CORRECTED - UPDATE 1-FDA adds black box to Genentech asthma drug Xolair

(Reuters) - WASHINGTON, July 2 - U.S. regulators on Monday finalized a strong new label warning patients and doctors about a potentially deadly allergic reaction from Genentech Inc.'s asthma drug Xolair. The U.S. Food and Drug Administration had proposed the so-called black box warning about anaphylaxis in February, but announced final wording of the label on Monday.



Xolair, given as an injection and known generically as omalizumab, is approved to treat adults and adolescents 12 years of age and older for moderate to severe asthma.


Read more at Reuters.com Government Filings News